Who is sponsoring HK-QIP?

HK-QIP is sponsored by AstraZeneca.

What drugs are being tested in HK-QIP?

Interventions: standard hyperkalemia management implementation.

What is the status of HK-QIP?

HK-QIP is currently RECRUITING.

Last reviewed 2026-03-09 · How we verify

Hyperkalemia Quality Improvement Program (HK-QIP) Study

NCT06884267 NA RECRUITING

This is a prospective, multi-center, single-arm study to evaluate the impact of implementation of guideline determined medical therapy (GDMT) for quality control improvement in non-dialysis chronic kidney disease (CKD-ND) patients, as well as provide evidence for standard hyperkalemia management with RAASi optimization in China CKD-ND patients.

Details

Lead sponsor	AstraZeneca
Phase	NA
Status	RECRUITING
Enrolment	1000
Start date	Wed Jun 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Nov 03 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hyperkalemia

Interventions

standard hyperkalemia management implementation

Countries

China